18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Global industry news
Pfizer's much-anticipated COVID-19 vaccine data has yet to materialize. Can it still roll out this year?
Merck looks ahead to a COVID drug and vaccine—and a Gardasil recovery—as pandemic takes a $2.5 billion toll
Indian drugmaker Cadila looks for outside production boost for COVID-19 vaccine: report
+7 495 442 37 85
+7 985 908 58 18
Registration of Medical Drugs in Russia
Registration of Pharmaceuticals in Russia
Registration of Pharmaceutical Dossier Variations in Russia
Registration of Pharmaceuticals in CIS
Clinical Studies in Russia
Clinical Studies for Registration of Pharmaceuticals in Russia
International Phase III Clinical Studies
Phase I, Phase II (IIa, IIb) Clinical Studies
Preclinical Studies in Russia
Preclinical Studies for Registration of Pharmaceuticals in Russia
Preclinical Studies for Registration of Biopharmaceuticals in Russia
In Vitro Preclinical Studies in Russia
Regulatory Consulting in Russia and EEU
Certification of Medical Drugs and Medical Devices in Russia
Registration of Medical Devices in Russia
Russian GMP inspection of pharmaceutical manufacturers
Regulatory Events Russia
Russian Regulatory News
You are here:
Pharegis LLC / ООО "Фареджис"
3-1 Begovaya str. ("NordStar Tower", 31st flr), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
TAX ID (TIN): 7718278100
+7 495 442 37 85 9am-6pm GMT+3
+ 7 495 442 37 85
+ 7 985 908 58 18
Send an Email
Send a copy to yourself
SHARE THIS BY:
Create an account
Forgot your username?
Forgot your password?
Drugs.com - New Drug Approvals
FDA Approves Veklury (remdesivir) for the Treatment of COVID-19
FDA Approves Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) Antibody Cocktail for Ebola (Zaire Ebolavirus)
FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
FDA Approves Alkindi Sprinkle (hydrocortisone oral granules) for Pediatric Adrenocortical Insufficiency
Simponi Aria (golimumab) Approved by the FDA for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
News and press releases
Strengthening global collaboration on COVID-19 real-world evidence and observational studies, , 23/10/2020
10th ESVAC report shows continued decrease in sales of veterinary antibiotics , , 21/10/2020
EMA virtual conference: 25 years of advancing public and animal health, , 19/10/2020
First long-acting injectable antiretroviral therapy for HIV recommended for approval, CHMP, 16/10/2020
Drugs.com - Clinical Trials
Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 (mRNA-1273)
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
October 23, 2020 -- Johnson...
FDA Authorises Restart of the COVID-19 AZD1222 Vaccine US Phase III Trial
23 October 2020 --...
CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate CVnCoV
TÜBINGEN, Germany /...
PharmaTimes: PharmaTimes Website RSS
Sensyne Health signs new NHS research agreement
Novartis’ rare renal disease candidate shows promise in phase II
Bayer’s Nubeqa wins NICE prostate cancer backing
AstraZeneca resumes US phase III COVID-19 vaccine trial
Evgen scores full approval for COVID-19 trial launch
Terms of Service
Sample Non-Disclosure Agreement